Jefferies Boosts Olema Oncology Price Target on Strong SERD Momentum
Jefferies raises Olema Oncology’s price target to $43 as new Roche giredestrant data strengthens confidence in next-generation SERDs and multibillion-dollar market potential.
Feed↓
/ What's going on?
Filter:
Hims Stock Dips as New SAFE Drugs Act Targets Compounded Weight-Loss Medications
Hims shares fell after lawmakers proposed the SAFE Drugs Act, a bill that would restrict compounded versions of popular GLP-1 weight-loss drugs. Analysts say the bill could significantly impact Hims’ fastest-growing product category.
Republicans Consider Medicare Hospital Pay Cuts to Counter Obamacare Subsidy Demands
GOP lawmakers explore site-neutral Medicare payments for hospitals as they search for alternatives to extending expiring Affordable Care Act subsidies affecting 20+ million Americans.
Amazon Expands Same-Day Grocery Delivery to 2,300+ U.S. Cities
Amazon's Same-Day Delivery service now offers fresh groceries in over 2,300 U.S. cities, challenging Instacart and Walmart+ with fast, temperature-controlled delivery for Prime members.
Instacart Under Fire: Same Item, Different Prices for Different Shoppers
Instacart accused of charging customers different prices for identical items through AI pricing experiments. Report finds price gaps up to 23%, potentially costing families $1,200 yearly.
Marvell CEO Denies Losing Amazon and Microsoft Deals, Says Data Center Business Is 'Rock Solid'
Marvell Technology CEO Matt Murphy denies reports of losing business with Amazon and Microsoft, stressing the company's "rock solid" data center relationships and calling the stock drop a buying opportunity.